Full Breakdown
WHO Issues Health Advisory on Contaminated Cough Syrups from India
10/14/2025, 3:49:54 AM
Overview of the Health Advisory
On October 13, 2025, the World Health Organization (WHO) issued a health advisory regarding three contaminated cough syrups manufactured in India. The affected products include specific batches of Coldrif from Sresan Pharmaceutical, Respifresh TR from Rednex Pharmaceuticals, and ReLife from Shape Pharma. The WHO warned that these syrups pose significant health risks, particularly to children, and can lead to severe, potentially life-threatening illnesses.
Recent Incidents and Health Risks
The advisory follows reports from India's Central Drugs Standard Control Organization (CDSCO) indicating that these contaminated syrups were consumed by children under the age of five in Chhindwara, Madhya Pradesh, resulting in at least 17 fatalities. The cough syrups contained diethylene glycol (DEG) in quantities nearly 500 times the permissible limit. DEG is a toxic industrial chemical that can cause severe health issues, including kidney failure, particularly in young children.
Historical Context of Contaminated Cough Syrups
The current incident is not isolated; it reflects a troubling pattern of substandard cough syrups linked to serious health crises. Since 2018, at least 12 cases of contaminated cough syrups have been reported in India. Previous incidents include the deaths of 12 children in India in 2019, 66 children in Gambia in 2022, and 68 children in Uzbekistan in the same year, all connected to Indian-manufactured products. The WHO has documented over 300 deaths related to contaminated medicines in a two-year period from 2022 to 2024.
Official Responses and Regulatory Actions
In response to the WHO's advisory, Indian authorities have urged the public to avoid the implicated cough syrups. The CDSCO confirmed that no contaminated medicines had been exported from India and that there is no evidence of illegal exportation. Following the advisory, manufacturers were instructed to halt production of the affected syrups.
Criticism of Regulatory Oversight
Critics have raised concerns about the effectiveness of India's drug regulatory system. Reports indicate that the use of toxic substances like DEG in children's medicines has persisted despite previous warnings. There are allegations that pharmaceutical companies have maintained political influence, resulting in inadequate regulatory enforcement and accountability for past incidents.
Conflicting Reports and Gaps
While the WHO and CDSCO have confirmed the contamination and its consequences, there are discrepancies regarding the total number of affected children, with some reports indicating that at least 23 children have died across Madhya Pradesh and Rajasthan. The full scope of the issue remains unclear, as the WHO continues to monitor the situation.
Verbatim Quotes
- “The WHO said the contaminated products pose significant risks and can cause severe, potentially life-threatening illness.” — World Health Organization
- “Even small amounts can destroy the kidneys, especially in children.” — Health Expert
- “India’s drug control system must be held directly responsible for the deaths of these children.” — Critic
This advisory highlights the urgent need for improved regulatory measures to ensure the safety of pharmaceutical products, particularly those intended for children.
